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Summary Background: Hypoxemic patients with Chronic Obstructive Pulmonary
Disease (COPD) have impaired cognitive performance. These neuropsychological
impairments are related to the degree of hypoxemia. So far, cognitive performance
has not been tested in non-hypoxemic patients with COPD.
Methods: We recruited patients with stable COPD and PaO248.0 kPa (60mmHg), as
well as healthy subjects, who were matched for age, intelligence quotient (IQ), and
level of education. Cognitive performance was studied by Stroop Colour Word Test,
Trailmaking, digit-symbol of the Wechsler Adult Intelligence Scale, addition subtest
of the Groningen Intelligence Test, and Story Recall.
Results: Thirty patients with COPD (FEV1 49.8% pred, mean age 64.8 yr) and 20
healthy volunteers (65.6 yr) were enrolled. COPD patients performed significantly
worse on trailmaking B, the digit-symbol test, and on the addition subtest. There
was no significant correlation between the tests of cognitive performance and
disease specific health status (Chronic Respiratory Questionnaire).
Conclusions: We conclude that even non-hypoxemic patients with COPD show
significant impairments in cognitive performance. These impairments are not
associated with deteriorations in health related quality of life. Prospective
evaluation of the impact of treatment on cognitive performance in non-hypoxemic
patients with COPD would be a logical subsequent study.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Since the seventies, cognitive performance has
been extensively investigated in hypoxemic pa-
tients with Chronic Obstructive Pulmonary Disease
(COPD). Patients in these studies in general had
severe COPD (FEV1o40% pred). Three methodolo-
gically sound, large-scale studies have been per-
formed in patients with mild hypoxemia,1
moderate hypoxemia,2 and mild to severe hypox-
emia.3 Impairments in abstract reasoning,1,2
memory,2 speed of performing1,2 and co-ordination
of simple motor tasks2 were found. Additionally,
significant correlations, though with low r-values,
were found between neuropsychological impair-
ments and partial arterial oxygen pressure in blood
(PaO2).
1–3 It has also been shown that cognitive
performance is affected in non-hypoxemic patients
with asthma.4 Therefore, we raised the question
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whether non-hypoxemic patients with COPD have
impairments in cognitive performance.
We compared the cognitive performance of non-
hypoxemic patients with stable COPD with a
healthy control group, which was matched for
age, intelligence quotient, and education level.
Our main hypothesis was that also non-hypoxemic
patients with COPD have impaired cognitive func-
tions. The test battery, we selected, tested for
memory, for speed of performance, and for cogni-
tion in routine operations. As it is conceivable that
cognitive impairments may have adverse effects on
daily life, the additional hypothesis was tested that
a negative correlation exists between presence of
such impairments and quality of life.
Methods
The Medical Ethics Committee approved the pro-
tocol. All subjects gave written informed consent.
Subjects
Patients in a stable phase of COPD, defined
according to the ATS criteria,5 were included when
X40 years, post-bronchodilator FEV1o85% pre-
dicted, and PaO248.0 kPa. Patients continued their
medication, and oxygen use was excluded.
Healthy volunteers were selected from an elec-
tronic database of a general practice. Every 20th
subject without a history of any major or chronic
disease was invited to participate by letter. Healthy
volunteers were matched with the COPD subjects
for age, level of education, and intelligence
quotient (IQ) as assessed by the Dutch version of
the National Adult Reading Test (NART).6 In both
groups, a history of alcohol or drugs abuse was
excluded, as were medication with known influ-
ences on cognition, oral corticosteroids or anti-
biotics in the last month, and anaesthesia during
the previous 6 months.7 Subjects with a history of
asthma, allergic rhinitis, or clinically relevant
diseases other than COPD were excluded. Subjects
with an IQ scoreo85 according to the NART were
also excluded.
Psychometric test battery
Nine psychometric tests were performed in a fixed
sequence as listed below, and lasted 50min.
The Stroop Colour Word test measures focused
attention by making use of response interference.8
In the first subtest, subjects are asked to read aloud
as quickly as possible words consisting of the colour
names yellow, green, red, and blue printed in
black. In the second subtest, coloured blocks should
be named. In the third subtest, the colour names
have been printed in ‘‘wrong’’ colours, e.g. the
word red in green print.8,9 All subtests are scored in
seconds above the predicted test duration, which is
based on gender and education level.
The Trailmaking from Halstead–Reitan battery
are visual search tasks requiring hand–eye co-
ordination and mental flexibility.10 In Trail A,
numbers have to be connected as fast as possible,
and in Trial B numbers and letters.
Story Recall studies direct and delayed recall
capacities.11 The investigator tells a story that
contains 20 meaningful elements. Patients are
asked to reproduce this text and the number of
reproduced elements is scored. After 15min the
delayed recall is tested.
In the Addition subtest of Groningen Intelligence
Test (GIT) subjects have to add three numbers. The
score is the correct number of additions during one
minute, and is a measure of cognition in routine
operations.12
Digit-symbol test of the Wechsler Adult Intelli-
gence Scale (WAIS) is a subtest from a widely used
intelligence test. Patients are presented with 100
symbols, which they have to code into numbers.
The number of correct substitutions in 1min is
measured.
Additionally, the Dutch version of the Chronic
Respiratory Questionnaire (CRQ) was administered
in the last 21 of the 30 patients with COPD.13,14
Statistics
Skewedness of distribution was assessed with the
Kolmogorov–Smirnov test. T-test or Mann–Whitney
U-tests, respectively were employed to evaluate
differences between healthy volunteers and pa-
tients with COPD. Correlations were evaluated by
Spearman or Pearson’s tests. Two-sided P-values
o0.05 were labelled significant. Additionally, if
parameters were normally distributed multivariate
analysis with correction for age and IQ was
performed.
Results
Subjects
Thirty-seven patients with a clinical diagnosis of
COPD were selected at the outpatient clinics.
Seven patients were subsequently removed from
the database; one because of a recent diagnosis of
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Alzheimer disease, 3 because of an exacerbation
requiring additional prednisolon treatment within
30 days before testing, and 3 because of a
PaO2o8.0 kPa. No patients were excluded on the
basis of an IQo85. A control group was formed that
was matched for age, IQ, and education level
(Table 1). Nearly all patients used steroids (n ¼ 28
of 30) and bronchodilators; 25 used anticholiner-
gics, 19 used 2-agonists, and 3 used theophyllines.
Cognitive performance
Patients with COPD scored worse than healthy
volunteers in three of the nine cognitive tests
(Trailmaking B, substitution, addition, and with a
similar trend in Trail A, see Table 2). Although
patients with lower FEV1 (o50% pred, being the
median value FEV1% pred) tended to score worse
than those with higher FEV1, this was significant
only for the Stroop Colour Word card (see Table 2).
None of the scores of cognitive performance
correlated significantly with FEV1% pred in patients
with COPD or with packyears in patients with COPD
or healthy subjects. A higher age correlated
significantly with inferior scores of Direct Story
Recall (r ¼ 0:34), Delayed Story Recall
(r ¼ 0:43), Trail A (r ¼ þ0:567) Stroop colour-
word card (r ¼ þ0:55), and the digit-symbol
(r ¼ 0:509). Similarly, a lower IQ correlated
significantly with poorer scores on the Stroop
word-card (r ¼ 0:43) and colour-word card
(r ¼ 0:46), delayed recall (r ¼ þ0:29), digit-
symbol (r ¼ þ0:52), and the addition subtest of
the GIT (r ¼ þ0:39). The latter four tests were
also significant correlated with level of educa-
tion (r ¼ 0:47; r ¼ þ0:37; r ¼ þ0:50; r ¼ þ0:49;
respectively). In other words, these scores were
better with higher level of education and IQ.
Given the observed association of cognitive
performance with age and IQ we re-analysed our
group differences correcting for age and IQ (IQ and
education level have a strong inter-correlation).
The differences between patients with COPD and
the healthy volunteers remained essentially un-
changed. Only the significance of the trail changed
to a lower level of significance (changed from P ¼
0:037 to 0.096).
In our group of non-hypoxemic patients with
COPD, we found no relation between PaO2 and the
test of cognitive performance.
Quality of life
We found no correlation between quality of life in
COPD patients (as measured by the CRQ) and the
test of cognitive performance, except for one test:
Trailmaking A was significantly related to CRQ
(r ¼ 0:619; P ¼ 0:005). There was also no sig-
nificantly correlation with the separate domains of
the CRQ. After correction for age and IQ, the
correlation between the total score of the CRQ and
the Digit-Symbol test became also significant.
Discussion
This study shows that in addition to the well-known
cognitive dysfunction in patients with COPD who
are hypoxemic, cognitive performance is also
impaired in non-hypoxemic patients, when com-
pared to subjects matched for age, education
level, and IQ. We found impairments in tasks
primarily evaluating the speed of information
processing. Memory and mental flexibility were
relatively undisturbed in our study.
There have been at least 11 studies with control
groups of healthy subjects investigating cognition
in patients with COPD1–3,15–22 and 3 looking at the
effects of oxygen therapy on cognitive perfor-
mance.19,23,24 It is difficult to compare the results
of these studies as they differ markedly in control
group, patient group (level of hypoxemia, severity
of COPD), and test batteries. Overall, these studies
indicate that the level of hypoxemia is important
for cognitive performance in COPD. Patients with
more severe hypoxemia have impairments in a
larger number of separate areas of cognitive
performance and these areas are more severely
impaired than in patients with mild hypoxemia.3
Furthermore, 8 out of 12 studies found a signifi-
cant correlation between PaO2 and measures of
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Table 1 Baseline characteristics.
COPD Healthy
N 30 20
Age (yr) 64.8 (8.2) 65.6 (11.2)
Gender (m:f) 23:7 10:10 F
FEV1(% pred) 49.8 (18.7) F F
PaO2(kPa) 10.1 1.1 F F
PaCO2(kPa) 5.3 0.7 F F
Pack years 22.1 (14.5) 10.3 (14.5)
IQn 103 (86–124) 102 (89–124)
Educationw 4 (1–6) 4 (1–6)
Data are expressed in mean (SD), education and IQ in
median (range).
nEstimate of intelligence quotient by Dutch read test for
adults.
w4 equals high school, 6¼ university.
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cognitive performance.1–3,15,18,20–22,25–28 Finally, a
significant positive effect of oxygen therapy on
cognitive performance has been observed.19,23,24
With a literature search we found five studies
with a comparable design in terms of control group,
test battery, and size of groups. Three of these
studies included COPD patients with moderate to
severe hypoxemia2,3,17 while two included COPD
patients with mild hypoxemia or no hypoxemia
(PaO247.3 kPa (55mmHg)).
1,20 The studies with
moderate to severe hypoxemia all found significant
cognitive impairments in COPD compared with
healthy controls.2,3,17 The studies with mild hy-
poxemic COPD patients reported normal20 or
reduced1 cognitive performance. In terms of
hypoxemia, the patients included in the study of
Prigatano et al.1 are nearest to our patient sample.
Although the mean PaO2 (without O2 therapy) of
their patients was 8.8 kPa (66.3mmHg), still 20% of
their patients were hypoxemic (PaO2o8.0 kPa
(60mmHg)). In our study, there were no hypoxemic
patients (mean PaO2¼ 10.1 kPa (75.9mmHg) and
our patients had less severe airway obstruction
(FEV1 49.8% pred) compared to the patients of
Prigatano (FEV136% pred). Still, we found compar-
able results on the tests used in both studies in that
patients with COPD scored worse than healthy
individuals (Trailmaking Aþ B and the digit-symbol
of the WAIS-test).
According to the literature, hypoxemia seems to
be the major factor in the development of
cognitive impairment in patients with COPD. How
can it be explained that this study shows cognitive
impairment even in non-hypoxemic patients with
COPD? Several explanations should be considered.
Firstly, even though we have included non-hypoxe-
mic patients, they may have had nocturnal desa-
turation, which can exist in patients with a daytime
PaO248 kPa (60mmHg).
29 Secondly, although all
patients had a PaO248.0 kPa it is possible that a
not fully normal PaO2, e.g. between 8.0 and
10.0 kPa, still leads to an impaired cognitive
performance. The finding that the PaO2 in our
range was not correlated to scores on cognitive
performance test argues against this reasoning.
Finally, other factors not related to hypoxemia may
also be responsible for the impaired cognitive
performance. The simplest explanation would be
that healthy people simply perform better than ill
people do. This ‘‘general illness hypothesis’’ has
already been refuted by a study of Grant et al.3
They found no correlation between health-related
measures like exercise capacity, psychological
measurements (total mood distress score of the
Profile of Mood States and Minnesota Multiphasic
Personality Inventory) and cognitive performance.
In accordance with their observation, we too could
not detect a significant association between FEV1,
quality of life, packyears, and cognitive performance.
Interestingly, our patients with COPD scored
poorly in particular on the 3 tests that measure
cognitive performance in a setting that also
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Table 2 Cognitive performance in patients with COPD in comparison with age-matched healthy individuals, and
in COPD patients with higher FEV1 compared to lower FEV1.
COPD overall COPD Healthy
FEV1pmediann FEV14mediann
N 30 15 15 20
Direct recall, items 18 (3–20) 18 (4–20) 18 (3–20) 19 (2–20)
Delayed recall, items 18 (0–20) 17 (4–20) 18 (0–20) 18.5 (2–20)
Time over Trail A, sec 48w (25–173) 57z,d (32–74) 40 (25–173) 40 (22–74)
Time over Trail B, sec 122z (54–235) 128w (54–235) 120 (64–181) 89 (41–163)
Stroop WC, sec above pred. 6 (17–40.5) 6 (17–40.5) 4.5 (10–18.5) 2.5 (6–16.5)
Stroop CC, sec above pred. 3 (18–31) 4.5 (18–31) 1 (17–14) 2 (12–36)
Stroop CW, sec above pred. 28 (6–164) 38.5w,z (2–164) 14.5 (6–80) 21 (19–68)
Digit-Symbol test (WAIS), n/min 34.5z (15–60) 32z (17–54) 35 (15–60) 47 (24–75)
Arithmetic part of GIT, n/min 9.5z (3–20) 7z (5–15) 11 (3–20) 11.5 (6–19)
Data are expressed in median (range), WC¼word card, CC¼ colour card, CW¼ colour word card. GIT¼Groninger Intelligence
Test. Sec¼ second, n/min¼ number in 1min. For exact units see methods. If results of a cognitive test were normally
distributed, results were corrected for age and IQ.
nMedian FEV1%pred was 50%pred.
wPp0.1, compared to healthy subjects.
zPo 0.05, compared to healthy subjects.
dPp0.1, compared to COPD, FEV14median.
zPo 0.05, compared to COPD, FEV14median.
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requires motor-muscle activity (Digit-symbol, Trail
B, and the additions subtest). This might be
compatible with the muscle weakness, that is
frequently seen in patients with COPD.30,31 We
cannot fully exclude that such muscle dysfunction
contributed to the measured impairments, next to
real cerebral cognitive dysfunction. However, the
trailmaking B and the Stroop colour word card
which were decreased especially in the patients
with low FEV1 put an increased claim on the
subjects’ cognitive abilities without requiring more
motor-muscle performance than their other subt-
est(s) (Trail A, Stroop word card and colour card).
So impairments in cognitive performance in our
results cannot simply be explained by muscle
dysfunction solely.
We assumed that impaired cognitive perfor-
mance of patients with COPD was related to
reduced scores on quality of life (QoL). Only the
score of the Trailmaking A and the Digit-Symbol
(after correction for age and IQ) were correlated
with the total score of the CRQ. Surprisingly this
correlation did not exist with the Trailmaking B,
while the Trailmaking A is easier to perform than
Trailmaking B. Because of the lack of correlation
with the Trailmaking B and the lack of correlation
between other test scores of cognitive performance
and (domains of) quality of life, we conclude that
cognitive impairments at least in non-hypoxemic
patients with COPD do not appreciably affect
quality of life, or vice versa.
There is no consensus about the optimal battery
of tests to use in a study of cognitive performance
in patients with COPD. Three studies used a small
number of tests to diagnose cognitive dysfunction16
or merely investigated one area of cognitive
performance.2,22 Although our test battery can be
criticised as being not as extensive as in the studies
of Grant et al.2,3 and Prigatano et al.,1 it tested
several relevant areas of cognitive performance.
In this study, nearly all patients used steroids (28
of 30) and bronchodilators (28 of 30). Therefore, it
was impossible to analyse the effects of medication
on cognitive performance. In a previous study, we
have shown that treatment of instable asthma
improved cognitive performance to the same level
as observed in healthy controls.4 Although the lung
function in patients with COPD is less responsive to
medication than asthma, it would be interesting to
analyse the effects of medication on cognitive
performance. Conversely, negative effects of med-
ication, such as theophyllines and b-mimetics on
cognitive performance cannot be ruled out.
At first sight, our study might be critized in some
aspects. Cognitive performance is assessed here
with 9 variables, two of which are subtests from
intelligence tests. However, cognition on some tasks
is influenced by IQ. Therefore, we excluded all
subjects with a low IQ and matched the participants
for the level of IQ (Table 1). In this way we ensured
that the differences we found in test of cognitive
performance were real differences in speed proces-
sing and not due to differences in IQ.
A second methodological point is that as it turned
out, we included more males in the COPD group
than in the control group. We do not think this has
influenced our results since the cognitive perfor-
mance tests we used are insensitive to gender, i.e.
in clinical practice the same norms are applied to
males and females.
Finally, we did not perform lung function and
arterial blood gas analyses in our healthy controls
and might therefore have erroneously included a
latent COPD in the control group. However if
anything, this misclassification would have led to
smaller differences instead of false positive ef-
fects.
In summary, this study shows significant impair-
ments in cognitive performance in non-hypoxemic
patients with COPD compared to healthy subjects.
We found impairments in tasks primarily investigat-
ing the speed of information processing. Memory
and mental flexibility were relatively undis-
turbed in our study. Quality of life is not related
to cognitive performance. Since medication can
improve cognitive performance in asthma, but
conversely for instance high dose of b-sympati-
comimetics or theophyllines could also conceivably
have negative effects, the effects of medication on
cognitive performance in non-hypoxemic patients
with COPD should be studied.
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